{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"6.1","upperLimit":"13.9","value":"7.9"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"120"}],"units":"Participants"}],"description":"Overall Survival was the time from first administration of study treatment until the date of death.","dispersionType":"95% Confidence Interval","groups":[{"description":"Belinostat 1000 mg/m\\^2 administered as a 30 minute IV infusion on Days 1-5 of every 3-week cycle until disease progression or unmanageable treatment-related toxicities.","id":"OG000","title":"Belinostat"}],"paramType":"MEDIAN","populationDescription":"Efficacy Analysis Dataset included participants who received at least 1 dose of belinostat and had a confirmed PTCL diagnosis.","reportingStatus":"POSTED","timeFrame":"24 months","title":"Overall Survival","type":"SECONDARY","unitOfMeasure":"months"}